Antibody Production Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Antibody Production Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The antibody production market is projected to register a CAGR of 12.16% during the forecast period (2022-2027).

The COVID-19 pandemic had a significant impact on the antibody production market. The government-imposed lockdowns, supply chain disruption, and trade bans in several countries have significantly reduced antibody production and supply during the pandemic. However, authorization of emergency use authorization for monoclonal antibodies as a treatment against COVID-19 by healthcare organizations maintained the demand for antibody production in the industry. For instance, the United States COVID-19 Treatment Panel recommended the use of monoclonal antibodies based on knowledge of the in vitro activities of the available products against the circulating SARS-CoV-2 variants and subvariants and some of the antibodies which are recommended in COVID-19 treatment are Bebtelovimab 175 mg intravenous injections for patients of age 12 years or less than 12 years, Bamlanivimab plus etesevimab, basiliximab plus imdevimab and few others. Thus, after the initial drop the demand for antibodies increased due to the pandemic, and this trend is expected to continue over the years owing to the long-term impact of COVID-19 on a person’s health.

The major factors for the growth of the antibody production market include the rising adoption of targeted immunotherapy, the increase in the R&D expenditure of pharmaceutical and biotechnology companies, and the rising demand for therapeutic antibodies. Antibodies are used in the treatment of various diseases, such as cancer, rheumatoid arthritis, and other chronic diseases. The targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells. As there is a rising prevalence of cancer, targeted therapies are getting more attention. For instance, According to the report of GOLOBOCAN 2020, there were 19.3 million new cases of cancer, and increasing cancer cases are the major growth factor behind the market. Some of the examples of monoclonal antibodies used in targeted therapies are bevacizumab, cetuximab, and ipilimumab.

The rising adoption of targeted therapies is expected to propel the overall growth of the antibody production market over the forecast period. Furthermore, there is an increase in R&D activities by most the pharmaceutical and biotechnology companies, to develop advanced biologics. The success rates and blockbuster sales of biologics have also made large pharmaceutical companies shift their presence to biopharma. Over the past two decades, the chimerization and humanization of mAbs (monoclonal antibodies) have led to the approval of several drugs & therapies for the treatment of autoimmune diseases, cancer, and transplant rejection.

However, the costs of anitbody production and stringent government regulations are expected to impede the growth of the market.

Key Market TrendsThe Monoclonal Antibodies Segment under the Antibody Type Accounted for the Largest Share in the Global Market

Monoclonal antibodies have large applications in the field of diagnostics, therapeutics, and targeted drug delivery systems, not only for infectious diseases caused by bacteria, viruses, and protozoa, but also for cancer, metabolic, and hormonal disorders. This segment is expected to account for the largest market share during the forecast period, owing to the rising investment in monoclonal antibody research and an increase in antibody-based product launches. Furthermore, there is a growing collaboration between pharma companies to develop advanced monoclonal antibodies. For instance, in May 2021, Cipla launched Roche’s antibody cocktail (Casrivimab and Imdevimab) in India for the treatment of mid- to moderate COVID-19 in adults and pediatric patients (12 years of age or older, weighing at least 40 kg). Additionally, global pharmaceutical companies are investing heavily in the R&D of cancer biologics drugs (monoclonal antibodies), because they are very efficient and non-toxic in the diagnostics and treatment of different types of cancer as compared to chemotherapy and other cancer treatment methods. These factors are expected to fuel the growth of the monoclonal antibodies segment in the coming years.

North America Accounted for the Largest Share in the Global Market

North America is expected to hold a significant share in the antibody production market and is expected to show a similar trend over the forecast period. The presence of favorable healthcare infrastructure and the rising prevalence of various chronic diseases, such as cancer are the major factors driving the growth of the market. As per the GLOBOCAN 2020 report, 2,281,658 new cancer cases were diagnosed and 612,390 deaths due to cancer in the United States alone. The cancer cases in Canada and Mexico were 274,364 and 195,499, respectively.

Furthermore, there is a rise in the approval of antibodies for the treatment of cancer and various types of diseases, which is one of the major factors contributing to the high growth of the market in the region. For instance, in November 2020, the Government of Canada and Eli Lilly signed an agreement for a monoclonal antibody therapy called Bamlanivimab (LY-CoV555) for COVID-19 developed by Eli Lilly Company.

Moreover, in July 2021, Cytiva and Pall Corporation signed a collaboration agreement for the expansion of manufacturing capacity and services across geographies to meet the growing demand for biotechnology solutions. Cytiva and Pall Corporation's capacity expansion will increase the manufacture of key products used to make biologic medicines. Therefore, these aforementioned factors are expected to boost the growth of the market in the region.

Competitive Landscape

The market studied is dominated by a few major players, and is expected to grow, owing to the rising collaboration and partnerships between pharmaceutical and biotechnology companies, in order to develop advanced antibodies. Some of the major key players in the global antibody production market are Danaher, Merck KGaA, Sartorious, ThermofisherScientific, and Eppendorf.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.